News | July 03, 2023
Sanofi reaffirms ambition to deliver >€10bn in annual vaccines sales by 2030
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Intent to start at least 5 innovative Phase 3 vaccine programs by 2025
Decisions on the marketing authorization for Rystiggo in the European and Japanese markets are expected in Q1 of 2024
Rapid card test kits for iScreen malaria card antigen (Pf/Pv) & iScreen dengue NS1
Granules India sponsored an initiative to ignite a drug-free revolution and contribute towards an empowered society
Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Oncodesign Services and ImaginAb sign a Preclinical License and Supply Agreement
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Ensitrelvir is an oral antiviral that suppresses the replication of SARS-CoV-2 by selectively inhibiting the viral 3CL protease.
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
Supply readiness follows months of manufacturing to ensure timely and ample supply
Subscribe To Our Newsletter & Stay Updated
